Cancer Cause and Prevention Research in District of Columbia
Cancer Cause and Prevention Research (93.393) awarded $61.2 million to recipients in District of Columbia in 45 grants from fiscal 2021 to 2025, 1.7% of the program's national total. Georgetown University received the most, $38.7 million.
- Awarded in District of Columbia$61.2 million
- Awards45
- Share of the program1.7%
- Rank among states15th of 48
- National total$3.6 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 21 | $11.0 million |
| FY 2022 | 27 | $11.7 million |
| FY 2023 | 29 | $12.9 million |
| FY 2024 | 24 | $11.5 million |
| FY 2025 | 27 | $14.0 million |
Recipients in District of Columbia
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Georgetown University | Colleges and universities | 24 | $38.7 million |
| George Washington University (the) | Colleges and universities | 16 | $19.2 million |
| Media Rez LLC | Small businesses | 3 | $2.4 million |
| Children's Research Institute | Nonprofits | 1 | $484,898 |
| American University | Colleges and universities | 1 | $396,041 |
Open opportunities under this program
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
See all 58 on the program page
Questions people ask
How much Cancer Cause and Prevention Research money goes to District of Columbia?
$61.2 million from fiscal 2021 to 2025, across 45 awards. District of Columbia ranks 15th of 48 states and territories for this program.
Who receives Cancer Cause and Prevention Research money in District of Columbia?
The largest recipient is Georgetown University, with $38.7 million in 24 awards. Next are George Washington University (the) and Media Rez LLC.
Can organizations in District of Columbia apply now?
Yes, 58 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Cause and Prevention Research in other states
Other large programs in District of Columbia
- National Railroad Passenger Corporation Grants
- Grants to States for Medicaid
- USAID Foreign Assistance for Programs Overseas
- Federal-State Partnership for Intercity Passenger Rail
- Greenhouse Gas Reduction Fund: National Clean Investment Fund
- Federal Transit Formula Grants
- International Programs to Support Democracy, Human Rights and Labor
- Environmental and Scientific Partnerships and Programs
- International Broadcasting Independent Grantee Organizations
- Highway Planning and Construction